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Abstract
Background: Many investigators are concerned that the modes of implementation and enforcement of the federal
regulations designed to protect children are unduly impeding pediatric clinical research.
Objective: To assess regulatory impediments to clinical research involving children and to develop
recommendations to ameliorate them.
Participants: The Pediatric Endocrine Society and The Endocrine Society convened a consensus conference
involving experts and stakeholders in patient-oriented research involving children and adolescents in 2008.
Consensus process: Following presentations that reviewed problematic issues around key regulations, participants
divided into working groups to develop potential solutions that could be adopted at local and federal levels.
Presentations to the full assembly were then debated. A writing committee then drafted a summary of the
discussions and main conclusions, placing them in historical context, and submitted it to all participants for
comment with the aim of developing consensus.
Conclusions: Recommendations designed to facilitate the ethical conduct of research involving children addressed
the interpretation of ambiguous regulatory terms such as “minimal risk” and “condition” and called for the
development by professional societies of best practice primers for common research procedures that would be
informative to both investigators and institutional review boards. A call was issued for improved guidance from the
Office for Human Research Protections and Food and Drug Administration as well as for the development by
professional societies of a process to monitor progress in improving human subject research regulation. Finally, a
need for systematic research to define the nature and extent of institutional obstacles to pediatric research was
recognized.
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Introduction: Pediatric-Specific Issues in Clinical
Research
Compliance with federal regulations often impedes the
transfer of basic scientific advances to the bedside [1].
Varying interpretation of these regulations by regulators,
institutional administrators, institutional review boards
(IRBs), accreditation agencies and investigators has exacer-
bated the burdens.
In conducting research to understand childhood dis-
eases and to develop optimal treatments, protection of
children is essential. However, to conduct research in
children, it is often necessary to enroll both unhealthy
and healthy children in clinical research that involves
some risk. Pediatric investigators share with Office of
Human Research Protections (OHRP), the Food and
Drug Administration (FDA), and IRBs the responsibility
to make research in children as safe and free from risk as
it can be without forfeiting the possibility of realizing the
scientific aims of the study. Regulatory burdens arise
from the inherent tension between the importance of
research and the need to protect children.
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The Code of Federal Regulations (CFR) includes both
general provisions for the protection of human research
subjects (the “Common Rule”, 45CFR46 Subpart A) and
special provisions designed to protect children (45CFR46,
Subpart D: Additional Protections for Children Involved
as Subjects in Research). In the last few decades enforce-
ment of these regulations increased appreciably and criti-
cal reports from the U. S. General Accounting office and
other federal agencies were accompanied by a series of
highly publicized federal shutdowns of prominent aca-
demic centers by the National Institutes of Health (NIH)
Office for Protection from Research Risks (OPRR) [2,3].
In 2000, OPRR functions were strengthened and trans-
ferred to the Office of the Assistant Secretary for Health
as OHRP [4]. Specifically regarding children, the Chil-
dren’s Health Act of 2000 [5-7] required all research
“conducted, supported or regulated” by the Department
of Health & Human Services (HHS) to comply with
45CFR46, Subpart D, and the Best Pharmaceuticals for
Children Act of 2002 [8] engendered an Institute of Med-
icine report on oversight of clinical research involving
children, including “the roles and responsibilities” of
IRBs [9]. One consequence of these events is that over-
sight by IRBs has been heightened, though not always
consistently applied, particularly where federal regula-
tions are ambiguous [3].
Parallel regulations from HHS and the FDA categorize
research that is permissible in children as follows:
1) research that does not involve greater than minimal
risk (45CFR46.404/21CFR50.51) (Table 1), 2) research
that includes interventions or procedures that present
more than minimal risk which, themselves, hold out the
prospect of direct benefit for the individual child-subject
(45CFR46.405/21CFR50.52), 3) research that includes
interventions or procedures that present more than mini-
mal risk which, themselves, do not hold out the prospect
of direct benefit for the individual child-subject and are
likely to yield generalizable knowledge about the sub-
jects’ disorder or condition (45CFR46.406/21CFR50.53)
(Table 2), and 4) research that presents greater than
minimal risk which is not approvable in categories 1-3,
but presents a reasonable opportunity to further the
understanding, prevention, or alleviation of a serious
problem affecting the health or welfare of children
(45CFR46.407/21CFR50.54) (Table 3).
The terms “minimal risk”, “minor increase over mini-
mal risk”, and “condition” are crucial to justifying any
pediatric research proposal. However, their ill-defined
nature has led to considerable variability in interpretation
of the regulations. They present to investigators and all
participants in the review and approval process a distinct
set of challenges over and above those involved in
research on adult subjects. Furthermore, research that
presents more than minimal risk to normal child-subjects
and no prospect of direct benefit is approvable only if it is
referred by an IRB to HHS for the opportunity for public
comment and for review by a panel of national experts in
pertinent disciplines to determine whether it is ethical
and meets the regulatory criteria for approval under
45CFR46.407/21CFR50.54. This national ethical advisory
panel is commonly called a “407” panel.
The Pediatric Endocrine Society and The Endocrine
Society are concerned that the modes of implementation
and enforcement of these regulations are unnecessarily
impeding essential research involving children. In making
a decision about any particular protocol, all the ambiguous
terms in the preceding paragraph must be interpreted by
researchers and IRB members; there is no explicit gui-
dance for doing so from OHRP or the FDA. The Societies
hosted a workshop to address these obstacles specific to
pediatric research on the 2nd day of a conference on Regu-
lation of Clinical Research hosted by the Societies on
November 5-6, 2008 in Bethesda, MD. The participants
were experts representative of the community of stake-
holders in patient-oriented research involving children as
subjects and included investigators, institutional adminis-
trators, IRB members, ethicists, and representatives from
professional societies, FDA, OHRP, the Clinical and
Translational Science Awards (CTSA) program, patients,
and patient advocates. The goal of the conference was to
find ways to facilitate the ethical conduct of research
involving children. The major thrust was to develop
recommendations for a) overcoming the regulatory bur-
dens imposed by variable interpretations of the minimal
risk standard and the definitions of “disorder” or “condi-
tion” and b) to facilitate the process for approval of an
intervention or procedure that poses a minor increment
over minimal risk for normal children. Subsequently
OHRP has announced proposals to improve the rules pro-
tecting human research subjects that seeks many of the
Table 1 Regulatory definition of minimal risk
45 CFR 46.102i: “The probability and magnitude of harm or discomfort anticipated in the research are
not greater in and of themselves than those ordinarily encountered in daily life or
during the performance of routine physical and psychological examinations or tests.”
Secretary’s Advisory Committee on Human Research
Protections recommendation (July 28, 2005):
For children below the age of legal consent, the standard “should be interpreted as
those risks encountered during daily life by normal, average, healthy children living in
safe environments...(and)...should be indexed to risks... experienced by children the same
age and developmental status as the subject population.”
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same goals, namely, to enhance protection for human
research subjects while reducing burden, ambiguity, and
delay for investigators [10]. It should be noted that issues
connected specifically to pediatric research are not
addressed by these proposals, but are left for future
consideration.
Methods
After presentations in plenary sessions by experts and gen-
eral discussion of the problems in regulatory terminology
and in studying “healthy” children (including those
selected because they are at risk of a disorder and those
who serve as “normal controls”), problem-solving work-
shops were held. Subsequently, following presentations of
conclusions from the workshops, potential solutions were
debated by the general assembly. A writing committee
then drafted a summary of the discussions and main
recommendations, placing them in the historical context
of the regulations.
Participants were given the opportunity to comment on
manuscript drafts and to approve, dissent, or abstain. Fifty-
five of the 69 conference participants with current
addresses (80%) responded [Appendix 1]. Of these, 28
approved, 25 abstained, and 2 dissented. All clinical investi-
gators approved (16) or abstained due to uninvolvement
(3); 8 ethicists approved, 2 abstained, 1 dissented; 11 IRB
members approved, 1 abstained, 1 dissented (some atten-
dees double-counted). Seven federal agency representatives
approved; the 10 OHRP and FDA representatives abstained
due to conflict of interest, though they provided technical
review, and the statements and conclusions in this docu-
ment do not necessarily represent their views or those of
HHS. Reasons for abstention not otherwise mentioned
included non-participation in pediatric workshops (9);
ambivalence about emphasis (2); or unstated (3). Dissents
were centered around the emphasis on problems at the
IRB and federal level rather than on investigator behavior,
the desire for fuller discussion of disagreements about the
consensus analysis of both the minimal risk standard and
the definition of “condition”, the proposed IRB appeal pro-
cess, and consensus recommendations to improve the 407
processes.
Case report
This case report was presented to illustrate the delays to
carefully designed research that can result from variability
in interpretation of the regulations. In this case the pro-
blems arose from the lack of a uniform standard for the
assessment of minimal risk and of a general understanding
about what constitutes a “condition”.
A multicenter national trial of oral insulin prophylaxis
involving children who were high-risk relatives of patients
with type 1 diabetes, identified by high titers of pancreatic
islet cell autoantibodies, was designed by a NIH TrialNet
subcommittee. This followed promising preliminary data
on a comparable subset of subjects in an antecedent
Table 2 Permissible research that poses more than minimal risk without direct benefit to the child-subject
45 CFR 46.406 (FDA 21 CFR 50.53 analogous). “Research in which the IRB finds that more than minimal risk is presented by an intervention or a
procedure that does not hold out the prospect of direct benefit for the individual subject...(and in which):
(a) The risk represents a minor increase over minimal risk;
(b) The intervention or procedure presents experiences to subjects that are reasonably commensurate with those inherent in their actual or
expected medical, dental, psychological, social, or educational situations;
(c) The intervention or procedure is likely to yield generalizable knowledge about the subjects’ disorder or condition which is of vital importance
for the understanding or amelioration of the subjects’ disorder or condition; and
(d) Adequate provisions are made for soliciting assent of the children and permission of their parents or guardians, as set forth in §46.408.”
Table 3 Conditions for federal approval of research that is not IRB-approvable according to any other regulatory
standards
45 CFR 46.407 (FDA 21 CFR 50.54 analogous). “Research not otherwise approvable which presents an opportunity to understand, prevent, or alleviate
a serious problem affecting the health or welfare of children. HHS will conduct or fund research that the IRB does not believe meets the
requirements of §46.404, §46.405, or §46.406 only if:
(a) the IRB finds that the research presents a reasonable opportunity to further the understanding, prevention, or alleviation of a serious
problem affecting the health or welfare of children; and
(b) the Secretary, after consultation with a panel of experts in pertinent disciplines (for example: science, medicine, education, ethics, law) and
following opportunity for public review and comment, has determined either:
(1) that the research in fact satisfies the conditions of §46.404, §46.405, or §46.406, as applicable, or
(2) the following:
(i) the research presents a reasonable opportunity to further the understanding, prevention, or alleviation of a serious problem
affecting the health or welfare of children;
(ii) the research will be conducted in accordance with sound ethical principles; and
(iii) adequate provisions are made for soliciting the assent of children and the
permission of their parents or guardians, as set forth in §46.408.”
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study [11]. The protocol was approved by the coordinating
center’s university IRB and subsequently by thirteen addi-
tional American IRBs. At a fourteenth IRB, however, the
process was protracted. In spite of the site investigator’s
responses to the IRB review in 2007, this IRB had major
persistent concerns that they could not approve research
that presented more than minimal risk in children who
were not ill (i.e., they did not have “a condition”) and, if
they indeed had a condition, the screening glucose toler-
ance test would be dangerous because of the high glucose
load. Thus, they planned to refer the protocol to OHRP for
407 review. The site investigator then submitted a written
appeal to the IRB citing two lines of evidence. First, the
investigator obtained a statement from their funding NIH
institute stating their interpretation of “condition”, which
accorded with recommendations discussed below. In addi-
tion, the investigator noted that an oral glucose tolerance
test in a 35 kg child involves ingesting less glucose (61 gm)
than is in a medium-size McDonald’s Hi-C orange drink
(64 gm). The IRB ultimately withdrew its request for a 407
review and approved the study 6 months after the initial
submission. After substantial disruption at the local
site, participation in the national trial was eventually
accomplished.
Regulatory issues hampering translational
research in children
1. Ambiguities in the regulatory definitions of “minimal
risk” and “minor increase over minimal risk”
Brief historical background
The National Commission for the Protection of Human
Subjects of Biomedical and Behavioral Research stated
that the principle of beneficence consisted in two ethical
imperatives: “do no harm” and “maximize possible bene-
fits and minimize possible harms” [12]. They sub-
sequently promulgated the standard for minimal risk as
that “normally encountered in the daily lives, or in the
routine medical or psychological examination of healthy
children” [13].
The Common Rule’s definition of minimal risk, (Table 1)
[5,7] derived from the National Commission’s recommen-
dations, has been widely endorsed by national and interna-
tional organizations, though not without controversy [14].
However, the thresholds for determining what constitutes
minimal risk remain undefined in the regulations. The reg-
ulations intentionally placed the responsibility for the
determination of the acceptable risk level for a research
intervention or procedure on each IRB. Although true to
the National Commission’s commitment to local control,
this approach promotes variation in application of regula-
tions and leads to variation in the capacity of researchers
to participate in well-designed and important multi-center
research in children and adolescents.
Subsequently the Secretary’s Advisory Committee on
Human Research Protections (SACHRP) made recom-
mendations for the interpretation of this regulatory lan-
guage [15] including the adoption of a “uniform standard”
for defining “minimal risk” – that of normal, average,
healthy children living in safe environments; they further
recommended that evaluation of minimal risk should be
indexed to risks in daily life and routine medical and psy-
chological examinations experienced by children the same
age and developmental status as the subject population
(Table 1).
The National Human Research Protections Advisory
Committee (NHRPC), the SACHRP predecessor, proposed
examples of equivalence of risk posed by particular proce-
dures (Table 4) [16], and SACHRP subsequently provided
congruent examples of minimal risk equivalents [15].
These examples addressed the nuances of specific situa-
tions in a general manner: for example, in placement of an
indwelling peripheral venous catheter, the level of risk was
considered dependent on other factors, such as age of the
child, the duration of catheter placement, number and
volume of samples, the setting in which the procedure is
performed and the experience of the operator.
Nevertheless, interpretation by IRBs of what tests consti-
tute a minor increase over minimal risk is notoriously vari-
able [17]. A survey of IRB chairs provided evidence for
both over- and under-protection. For example, a single
venous blood draw was categorized as minimal risk by
81% of IRB chairs, greater than minimal risk by 19%. A
magnetic resonance scan without sedation was considered
to constitute minimal risk by 48%, a minor increase over
minimal by 35%. A weekly blood draw of 10 ml for 6
months was considered to constitute minimal risk by 15%,
a minor increase over minimal by 51%. A pharmacokinetic
study (risk of death: 1/100,000) was considered as minimal
risk by 7%, a minor increase over minimal by 30%. Initial
testing of a drug in children found safe in 500 adults was
considered minimal risk by 5%, a minor increase over
minimal by 23%. In each of the above cases, the remainder
considered the risks to be more than a minor increase
over minimal. Participant payment was incorrectly consid-
ered a direct benefit by 10%.
If an IRB finds that elements of the research pose
more than minimal risk, it must decide if they are
approvable because they have the potential to directly
benefit the child (45CFR46.405/21CFR50.52) or meet
the criteria of the other CFR sections discussed below.
Discussion of the regulatory minimal risk standard
Ethical considerations seldom (if ever) permit research in
which one deliberately inflicts harm on a particular sub-
ject no matter how great the intended benefits. Neverthe-
less, there are well-established criteria for ethical
justification of a statistical probability of harm. Standards
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set forth in 45CFR46.405/21CFR50.52 specify, for exam-
ple, that the hazards associated with the development of
cancer chemotherapies are justifiable by anticipated
direct benefit to the subject [18]; however, such justifica-
tion may be difficult to support in phase I oncology stu-
dies. 45CFR46.406/21CFR50.53 permits and specifies the
conditions for justification of the imposition of a statisti-
cal possibility of harm to child-subjects for the benefit of
their class of children. In the interpretation of these cri-
teria, IRBs generally require that either the probability or
magnitude of harm (preferably both) be small.
It is generally agreed that the Common Rule definition
of minimal risk is ambiguous and that there is evidence
for a substantial degree of inconsistency across IRBs in its
interpretation [14]. The conferees concluded that revising
the definition in federal regulations would be not only dif-
ficult, but potentially counterproductive; the ambiguity
guards against the risk of inflexible interpretation and the
politicization that could be engendered by an effort to
amend the Common Rule by legislation with more precise
but constrained definitions.
Therefore, the challenge is to find ways to improve
implementation of the existing regulations. The experi-
ence in this era of multicenter trials, exemplified by the
case report, suggests that more uniformity in IRB imple-
mentation of the regulations would be desirable. As we
strive to develop the desired uniformity, we must take
steps to ensure that the uniform interpretations and their
implementations are transparent and reflect the views of
the patient community as well as the carefully considered
judgments of appropriate experts who are fully familiar
with the field and the problems it faces. We must also be
on guard to prevent excessive rigidity which might tend
to stifle investigators’ and IRBs’ efforts to develop creative
solutions to difficult problems.
NHRPAC and SACHRP recommendations for the
interpretation of the minimal risk standard include
recognition that the local context in which research is
conducted–the expertise and experience of the investiga-
tor, as well as the depth and track record of expertise at
the site–are important determinants of risk [19,20].
While the standard (Table 1) directs IRBs to compare
the “probability and magnitude of harm or discomfort
anticipated in the research...to those ordinarily encoun-
tered in daily life”, a data-driven, evidence-based assess-
ment of relative risk, as advised by SACHRP [15], does
not often seem to have been adopted as the basis of deci-
sion-making, as exemplified by the case report and evi-
dence from analysis of national advisory panel reviews
[21]. Furthermore, it seemed to many participating inves-
tigators as if ‘the discomforts of daily life’ are underesti-
mated by IRBs, which leads to overestimates of risk.
“Discomfort” generally differs from “harm” with respect
to duration, cumulative characteristics, and irreversibility
[15,22]. Discomfort does not usually involve irreversible
damage/injury or protracted/severe pain. Thus, discom-
forts seldom pose more than minimal risk of harm. The
discomforts ordinarily encountered during childhood in
optimal environments can be considerable (bad colds
and gastroenteritis, for example).
SACHRP has also recommended that the evaluation of
minimal risk should be indexed in equivalency to risks
experienced by children the same age and developmental
status as the subject population [15]. As the child gets
older–from 8 to 12 years, for example–there are at least
two relevant developments [23,24]. 1) His or her ability to
perform the cognitive procedures necessary to give assent
increases; there is maturing of the ability to engage in con-
crete and abstract reasoning and there is development of a
sense of privacy that increasingly resembles that of an
adult. 2) The child increasingly engages in activities that
move the boundary of what counts as, or exceeds, minimal
risk. An extension of this concept is that adolescents’
advancing capacity for and experience with mature deci-
sion-making, for example, in health matters and under-
standing of altruism, gives them the potential to give the
Table 4 Examples of estimates of procedural risks
Procedure Minimal risk Minor increase
over minimal
More than
minor increase
over minimal
Comment
Venipuncture X
Indwelling peripheral venous catheter X Risk level may be raised by other factors
Wrist-hand x-ray X
Bone density test X
Oral glucose tolerance test X
Skin punch biopsy with topical pain relief X
Organ biopsy X
MRI, no sedation X Risk level may be raised by other factors
MRI, with sedation X Intubation may decrease risk for certain children
Abridged from NHRPAC (2002).
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ethical equivalent of informed consent, so consideration
should be made for allowing them to participate in certain
types of research without permission of parents or guar-
dians [20,25]. Thus, it seems reasonable to conclude that
developmental- and age-appropriate assent parameters
should allow children, particularly adolescents, to partici-
pate in individual decisions about the degree of risk that
they would be prepared to tolerate in relation to the
anticipated benefit they perceive in participating in appro-
vable research. While adolescents choose more risky beha-
viors than adults do, which may be a reason for pause
regarding adolescents, minimal risk should be evaluated in
the light of risks to which the child/adolescent ordinarily
is exposed and the varying autonomy that adolescents are
ceded. Defenses against choices of excessively risky activ-
ities in research include the requirements for IRB review,
for parental or guardian permission and, in the absence of
permission by parents or guardians, the requirement by
45CFR46.408(c) of a protective mechanism comparable to
that ordinarily afforded by such permission [6]. The regu-
lations do not suggest any such protective mechanisms;
however, the National Commission offered several sugges-
tions, for example, the appointment of “a social worker,
pediatric nurse or physician to act as a surrogate parent...”
[13].
The provision in 45CFR46.408(c) that parental or guar-
dian permission may be waived “if the IRB determines
that a research protocol is designed for conditions or a
subject population for which (such permission) is not a
reasonable requirement” reflects recommendations of the
National Commission [13]. The regulation names only
one of the several circumstances mentioned by the
National Commission for which such waivers would be
appropriate–viz, “neglected or abused children”. Among
the other circumstances mentioned by the National
Commission - one that is widely recognized by IRBs - is
“[r]esearch designed to identify factors related to the inci-
dence or treatment of certain conditions in adolescents
for which, in certain jurisdictions, they may legally
receive treatment without parental consent....”
In the time of the National Commission’s discussions
of “diseases for which adolescents may obtain treatment
without parental permission,” there was focus on more
or less specific diseases or conditions, such as sexually
transmitted diseases, drug abuse, and issues of birth con-
trol. Subsequently, many states have enacted laws permit-
ting qualifying adolescents to receive care independent of
parental permission and, in most cases, parental knowl-
edge. This development expanded greatly the category of
diseases or conditions for which adolescents may obtain
treatment without parental permission. For many adoles-
cents, this category of their activities includes most or all
of their health care services [25,26]. However, federal
research regulations do not preempt state consent laws,
and the “mature minor” doctrine is not settled law in all
states. Likewise the legal limits on a parent’s ability to
consent to non-beneficial, more-than-minimal risk
research are not resolved in some states, such as Mary-
land as evidenced by the Grimes vs Kennedy Krieger
Institute case [27]. As a result, each institution must
determine what limits are consistent with its state law.
Investigators are concerned that, in enforcing the reg-
ulations for obtaining permission from parents and
assent from children (45CFR46.408), IRBs tend to over-
protect children from risk because of concern about
child exploitation, by parents as well as investigators,
and place insufficient emphasis on the importance of
assent. This propensity of IRBs may inflate the estima-
tion of risk and thus hinder participation in studies by
children who may be mature enough to reasonably
assess risk. The proper role of the IRB must be to objec-
tively determine the upper level of risk in a protocol
that will be treated as minimal for children in particular
age groups and ensure that there is nonbiased represen-
tation of risk so as to avoid pressure from parents or
investigators to either participate or not participate in
the research. IRB approval then allows children to assent
or dissent after participation in the discussion about
whether the proposed risk is acceptable.
Assent is the child’s affirmative agreement to partici-
pate in research. Of course, this decision is influenced by
parental attitudes, and the child does not have the ulti-
mate authority to decide whether to accept or decline.
To the extent that the child has the capacity to partici-
pate, her or his opinions should be given proportional
weight. While a four-year old’s cognitive development
does not allow many of the operations needed for assent,
they are capable of choosing not to participate. Further-
more, a child’s actions that rescind assent and/or other-
wise constitute “dissent”, i.e., deliberate objection, based
on their changing evaluations of the acceptability of the
risk, are clearly recognizable and are decisions that must
be honored [28].
The general consensus was that HHS acceptance of
NHRPAC and SACHRP recommendations for interpre-
tation of the minimal risk standard would be an impor-
tant step toward implementing a systematic method for
IRB decision-making.
The conferees discussed the development by national
subspecialty professional societies of “best practice pri-
mers” for common research procedures that would be
informative to both investigators and IRBs to facilitate
systematization of their estimates of risk. Initial steps in
developing these primers should be circumscribed, how-
ever, to avoid premature expansion that would require
societies to develop elaborate support infrastructure.
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Recommendations regarding interpretation of the minimal
risk standard
1. The conferees support and endorse the “daily life”
and “routine medical or psychological examination or
tests” Common Rule threshold as the criteria for esti-
mating minimal risk for both harm and discomfort.
2. Investigators bear the responsibility to brief IRBs
with facts and arguments to support a regulatory assess-
ment of the level of risk and benefits in spite of the
ambiguities in the regulatory definition of minimal risk.
3. To improve IRB implementation of the regulations,
the conferees recommend that OHRP/FDA adopt the
SACHRP recommendations as guidance for defining
“minimal risk” and “minor increase over minimal risk”,
and recommend publishing examples of procedures or
interventions that meet these criteria.
4. Professional societies should develop “best practice
primers” for common research procedures suitable for
use by both investigators and IRBs that address both the
proper performance and degree of medical risk posed by
procedures.
5. Individual children should be allowed the opportu-
nity to participate in deciding upon involvement in a
particular procedure or intervention in accordance with
their developmental age, subject to parental acquies-
cence or refusal.
2. Burdens arising from ambiguities in the interpretation
of what constitutes a disorder or condition (re
45CFR46.406/21CFR50.53, Table 2)
Brief historical background
Under the “406/53” category of the federal regulations,
non-beneficial interventions or procedures involving a
minor increase over minimal risk may be carried out in
child subjects with a disorder or condition if they are likely
to yield important generalizable knowledge about the sub-
jects’ disorder or condition, and other specifications are
also satisfied (Table 2) [6]. This regulation is based on the
premise that some such research can be justified ethically
notwithstanding potential risks [12,18]. While it would be
desirable not to expose children to any risk of research,
research on childhood disorders or conditions cannot by
its very nature be conducted on adults. Without such
research, children would be left with an uninformed, static
standard of care. The leading international documents on
the ethics of medical research endorse the concept that
“low risk” research is permissible in children under these
circumstances, though variations in defining the permissi-
ble burden of risk reflect the underlying complex ethical
issues [29-32].
The term “condition” is even less well defined than
“minimal risk.” The federal regulations offer no defini-
tions of either “condition” or “disorder.” The regulations
on conditions stem from the 1977 National Commission
report that “it is necessary to learn more about normal
development as well as disease states in order to develop
methods of diagnosis, treatment and prevention of condi-
tions that jeopardize the health of children, interfere with
optimal development, or adversely affect well-being in
later years” [13]. Because this report did not define “con-
dition,” there is continuing controversy about whether a
condition includes predisposing factors such as obesity,
genetic risk, or vulnerability as part of a population at
risk.
NHRPAC subsequently proposed that, “a condition
relates to a specific characteristic which describes a group
of children, or to a physical, social, psychological or neuro-
developmental condition affecting children, or to the risk
of certain children developing a disease in the future based
on diagnostic testing or physical examination” [16].
NHRPAC provided the following as examples of condi-
tions: infancy or adolescence (i.e., normal developmental
periods of a child’s life); socioeconomic circumstances
(e.g., poverty and institutionalization); and a specific devi-
ant property (e.g., genetic) that would predispose the indi-
vidual to the subsequent development of a disease.
However, SACHRP endorsed the Institute of Medicine
2004 advice [33] that “condition” be interpreted slightly
more specifically in determining whether proposed
research involving a minor increase over minimal risk and
no direct benefit can be approved under 406/53. They
recommended that “the term condition should be inter-
preted as referring to a specific (or a set of specific) physi-
cal, psychological, neurodevelopmental, or social
characteristic(s) that an established body of scientific or
clinical evidence has shown to negatively affect children’s
health and well-being or to increase their risk of develop-
ing a health problem in the future” [15]. Neither HHS nor
FDA has issued guidance on this definition.
Discussion of defining “condition”
The definition of “condition” is variously interpreted in the
absence of specific guidance, as exemplified in the case
report about children at risk for type 1 diabetes. Scientific
progress is identifying an increasing number of conditions
as posing significant risk for the development of a health
problem (e.g. genetic variants, obesity). The SACHRP defi-
nition is seen by investigators as acceptable providing that
“shown” be interpreted as “indicated” so as to avoid the
excessively high bar that might be imposed before risk can
be conclusively proven.
While both NHRPAC and SACHRP recognized there
are times when a cohort of normal healthy children may
be considered as having a condition appropriate for
research under 406/53 because they are part of a vulner-
able population, NHRPAC’s wording is somewhat
broader. Infancy and adolescence are vulnerable develop-
mental periods in many areas (e.g., neuropsychological,
endocrinological). SACHRP provided the example of
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vaccine studies for common childhood diseases, where
healthy children are at risk. Subsequent studies of human
papillomavirus vaccine in healthy adolescents were thus
in harmony with SACHRP recommendations. An analo-
gous example in endocrinology would be hormonal stu-
dies that involve novel testing protocols in normal
adolescent girls to understand the basis of the high pre-
valence of adolescent menstrual dysfunction that may
have long-term health consequences [34].
Recommendations regarding interpretation of “condition”
1. To improve implementation of the regulations by
IRBs, the conferees recommend that OHRP/FDA
essentially adopt the SACHRP interpretation of “disor-
der or condition”. This would clarify that considera-
tions such as obesity or heritable risk factors for the
disorder under study are conditions relevant to an
otherwise healthy child-subject’s current or future well-
being and that a cohort of normal healthy children may
be considered as having a condition appropriate for
research because they are part of a vulnerable
population.
3. Burdens arising in the approval process for an
intervention or procedure that poses greater than
minimal risk for normal children with no prospect for
direct benefit (re 45CFR46.407/21CFR50.54, Table 3)
Brief historical background
Interventions and procedures that present more than
minimal risk and no prospect of direct benefit to children
who have no disorder or condition (as defined previously)
are regulated according to the “407/54” category (Table 3).
As noted earlier, such research was a major focus of this
conference. Research in normal children is sometimes
required to generate control or normative data. This regu-
lation is based on the premise that such research can
sometimes be ethically justified [12,18].
If U.S. Department of Health and Human Services funds
are involved, IRBs are required to refer protocols in this
category to HHS for review by a federally-convened 407
panel to ensure that any research carried out under this
category is ethical. If supported by other federal agencies
or a non-federal sponsor, OHRP recommends that the
institution carry out a similar process for expert review
that includes the opportunity for community comment.
This review process was shortened to its current form in
2003, and OHRP and FDA guidance on this topic was
issued in 2005-2006 (Figure 1) [5,35].
Participation in research by normal children that does
not confer direct benefits may confer indirect benefits. Ack-
erman suggests that one indirect benefit of involvement of
normal, relatively mature children in research is raising the
child with social awareness – one who would want to con-
tribute to the well-being of the community [36]. Such
research participation has been likened by McCormick to
an act of charity that one should perform when one can do
so without bearing too great a burden [37]. Wendler and
Jenkins argue that such participation differs from usual acts
of charity in that it is sacrificial, i.e., something is being
done to the child, not by the child [38]; the fact remains
that the child’s assent is a charitable act which is “done by
the child”. While the child may consider money to be a
benefit of participation in research, OHRP prohibits IRBs
from considering payment as a direct benefit of the
research when assessing the balance of risks and benefits.
When presented with a protocol in which greater than
minimal risk is to be presented to an apparently normal
child, an IRB must make two determinations. First, it must
determine that the research is not approvable under
§46.404/§50.51, 405/52, or 406/53. If an IRB considers the
proposal unethical, it is expected to disapprove the proto-
col. If the IRB finds the minimal risk nature of the
research to be unclear or determines that there is greater
than minimal risk and it deems the research to be ethical
and important, it must refer to an HHS 407 determination
process for approval.
If an FDA-regulated product is involved, even if being
used according to the label, this 407 review is conducted
by the Pediatrics Ethics Subcommittee of the FDA Pedia-
tric Advisory Committee. Because the regulation calls for
the “opportunity for public review and comment”, these
reviews have been conducted in a public forum although
this is not a requirement. This Committee then makes its
46.407/50.54
Public comment
Expert Panel:
Pediatrics Ethics Subcommittee
Pediatrics Ethics Committee (FDA)
FDA Commissioner OHRP IRB
Secretary, HHS
Public comment
(1) (2)
(3)
Figure 1 Process for OHRP-FDA joint review of “407” referral
(under 45CFR 46.407/21CFR50.54). A referral involving an FDA-
regulated product is submitted to OHRP, which convenes a 407
panel, meanwhile posting the submission for public comment. The
Pediatric Ethics Subcommittee of the FDA Pediatric Advisory
Committee reviews the submission and, in a public forum, makes a
recommendation to the FDA Pediatrics Advisory Committee. The
recommendation of the latter is forwarded to the FDA
Commissioner and OHRP, which submit their recommendation to
the Secretary, HHS for approval (1), who then (2) directs OHRP to
provide feedback (3) to the IRB. If OHRP feedback involves
stipulations, the IRB responds directly to OHRP.
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recommendation to the FDA Commissioner and the
Secretary of HHS for a determination.
Between 1991 and 2010 there were twenty two 407
referrals, of which 17 involved normal child subjects in
varying roles in the research design, including in a control
group, as healthy donors, and as healthy volunteers. Six of
the 22 studies have been approved, 4 disapproved, and 12
withdrawn. Reasons for withdrawal were diverse: reconsi-
deration by IRBs resulted in determinations that the
research was approvable under 45CFR46.404, 46.405, or
46.406 (n = 4); the investigator decided not to pursue the
study (n = 6), time in review playing a role in some of
these decisions; or the study site was dropped from a
multi-center study (n = 2). Only 7 of the 22 referrals have
occurred since 2005 under the current review system: 4 of
these were withdrawn, 3 approved. Median time from sub-
mission to OHRP until approval with stipulations was 10.2
months (range 8.3-10.9); median time until final approval
was another 7.75 months (5.2-11.9).
Discussion of challenges posed by the 407 process
The challenge for institutions and IRBs is how to enable
important research that will advance science and combat
disease to move forward in a timely manner, while addres-
sing the regulatory requirements. This involves keeping in
mind the primacy of protecting children, while avoiding
the overprotection that stymies appropriate research.
Scientific advancement requires the ongoing development
of control/normative data. The 407 process of approving
studies in normal children can take years for a relatively
straight-forward case, with about one-third of this time
being spent in federal review and two-thirds in local
review [39]. The conferees are concerned that investigators
avoid proposing such research in children because 407
referral is such a daunting and time-consuming prospect,
during which funds and resources can evaporate.
A major cause of the delay is uncertainty about what
constitutes a minor increase over minimal risk on the part
of both investigators and IRBs. It is incumbent upon both
investigators and IRB members to become knowledgeable
about the regulations. Too often, investigators fail to make
a specific argument as to whether an intervention presents
minimal risk or minor increase over minimal risk. Too
often, IRB members are ill-prepared to render opinions
based on scholarly familiarity with the regulatory issues
involved [40]. Thus, it is important that investigators’ pro-
tocols include IRB-targeted arguments in IRB-relevant lan-
guage about risk and that IRB members be thoroughly
familiar with the regulations and their implications.
The local delay stems in part from IRB tendencies
toward over-protection in categorizing risk in children
[21]. Differences in perception of risk cause disagree-
ments between the IRB and investigator about the need
for the 407 process, as in the case report. In part, IRB
conservatism is thought by the conferees to result from
overzealousness prior to facing the intense OHRP scru-
tiny that comes with the 407 process. IRBs and the insti-
tutions that they serve operate in defensive mode partly
as a reaction to the history of punitive actions by OHRP
and its predecessor, the criteria for which remain unclear.
Since the 407 process itself can be streamlined very little
unless redesigned, it behooves IRBs that face the prospect
of 407 referral to consult with OHRP promptly to mini-
mize the time to referral, rather than to try to first perfect
their paperwork.
Part of the local delay relates to IRB members’ uncer-
tainty about risk/benefit categorization because they
often lack expertise on which to make an accurate judg-
ment of risk of harm and tend to underestimate the
ordinary risks and discomforts of daily life. A single
source of data about 407 outcomes in summary form to
which IRBs can turn for precedent, analogous to a “case
law” approach, would be helpful to IRBs and investiga-
tors. While the OHRP website provides links to the
details of protocols reviewed since 2002 [5], there is no
executive synopsis that abstracts the critical research pro-
cedures with a summary of the conclusions about the
degree of risk they pose and the context in which they
were found approvable. Such a synopsis would be an
important educational tool. A model for this kind of
activity was presented by the publication of case studies
as a regular feature in the first several years of publication
of IRB: A Review of Human Subjects Research.
One model to reduce such delays could be development
of regional or national pediatric IRB expert consultative
panels to address the challenge of assembling appropriate
pediatric expertise in a single institution, especially when
the only expert available is one of the investigators, whose
participation in the ethical review must be limited [41].
These consultative panels would likely be “virtual”, con-
vened upon demand and constituted with sufficient pedia-
tric and scientific expertise to render an opinion on a
proposed protocol upon referral from the institutional
IRB. Their authority would be limited to advisory unless
the necessary paperwork were accomplished to include
them in a Federal Wide Assurance as IRBs and to establish
the required inter-institutional agreements. Another
option could be provision by professional subspecialty
societies of expert review panels and the development of
the aforementioned “best practice primers” for common
research procedures.
A possibility to facilitate 407 reviews for federal grant
applications, which already involves a prolonged process,
would be to link them to the federal scientific grant
review process. While the study sections have the scienti-
fic expertise and are required to assess risk and approve
the appropriateness of all human research, most of them
are not broadly constituted with expertise in interpreting
ethical standards or the regulations on which they are
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based, nor do they have the regulatory authority to serve
as ethics review panels [28]. A workable system might
involve sequential review, with the ad hoc addition of
specific ethical and regulatory expertise on the scientific
review panels, and a representative of the scientific
review panel on the subsequent federal ethics panel.
Several investigators voiced concern about the adversar-
ial attitude of IRBs and expressed their opinion that those
that do not proactively communicate directly with investi-
gators as a matter of local institutional policy are not
receptive to alternative conclusions about risk. This can
lead to misclassification of children as requiring 407
review, as in the case report, or it can lead to inappropriate
rejection of studies of normal children and refusal to refer
for 407 review. There is no widely accepted mechanism by
which an investigator can challenge an IRB’s disapproval.
An “appellate IRB process” has been proposed to respond
to the need for due process for rejected applicants [40].
Guidance from OHRP as to the desirability of direct com-
munication with investigators and the availability of appel-
late mechanisms would be helpful to many investigators.
Institutions are unlikely to change such policies without
guidance from a regulatory agency.
The 407-approval mechanism also was noted to contain
both procedural and interpretive ambiguities that raise
ethical concerns, namely about the scope of the informa-
tion offered to the public for comment and its potential
conflicts with investigators’ intellectual property or com-
mercial interests. Also unclear is whether there is any
upper limit to permissible levels of risk for interventions
that do not hold out the prospect of direct benefit.
Recommendations regarding improving the “407” process
1. OHRP/FDA should provide executive summaries of
407/54 determinations.
2. Specialty societies should establish summary state-
ments of procedures considered to be of minimal risk to
child subjects as established by precedent and data
regarding risk.
3. OHRP/FDA should provide guidance that
encourages direct discourse between IRBs and investiga-
tors and that supports the availability of institutional
appeal processes.1
4. OHRP/FDA should provide guidance for the develop-
ment of a national process analogous to the federal judicial
system by which investigators can appeal an IRB decision,
once local mechanisms have been exhausted. This would
provide recourse for investigators who believe that risk to
children has been improperly categorized. Examples
would include concerns about IRB inability to provide
adequate scientific review, misclassification of children at
risk as requiring 407 reviews, or refusal to refer for 407
reviews.
5. OHRP/FDA should encourage IRBs to actively
interact with them to minimize paperwork and facilitate
consideration of protocols for which 407 review is being
considered.
6. Where applicable, federal granting agencies should
consider means of coordinating 407 regulatory review
with the federal scientific review process.
Conclusions: Summary of recommendations for
overcoming regulatory burdens in research
involving children
Regulatory burdens hampering translational and other
research in children arise from two major ambiguities in
the terminology of the regulations. These are: 1) the ambi-
guities defining “minimal risk” and a “minor increase over
minimal risk”, and 2) ambiguities in defining a “condition”
or a “disorder” and problems with interpretations of the
regulations by IRBs.
These ambiguities lead to a protracted approval process
for interventions or procedures judged to pose more than
minimal risk for normal child research subjects. They
cause different IRBs to decide similar cases differently.
This is a particular problem for multicenter studies that
must get approval from multiple IRBs.
These problems have been recognized for years. The
Secretary’s Advisory Committee on Human Research Pro-
tections (SACHRP) has built on the National Human
Research Protections Advisory Committee (NHRPAC)
and Institute of Medicine conclusions on this matter to
issue content for recommended guidance in 2005; it trans-
mitted its proposal to the Department of Health and
Human Services (HHS) Secretary, who, in turn, recom-
mended moving forward. Now, over 5 years later, the
Office for Human Research Protections and the Food and
Drug Administration (OHRP/FDA) have not issued expli-
cit guidance that would directly implement these
guidelines.
We recommend that federal agencies adopt these stan-
dards as guidance to allow more consistent interpretation
of the regulations. This will not accomplish total consis-
tency among IRBs, but would provide a common basis for
decision-making. Professional societies can aid in this pro-
cess by developing “best practice primers” for common
research procedures suitable for use by both investigators
and IRBs that address both the proper performance and
degree of risk posed by commonly used procedures.
We also recommend that IRBs avoid considering chil-
dren as a single group and instead recognize the increased
experience, understanding and self-determination in older
children and adolescents. This process, along with allevia-
tion of other IRB procedural burdens, could be facilitated
by explicit OHRP/FDA guidance.
Finally, we recognize that most of concerns about the
nature and impact of regulatory burden are based on the
opinions of investigators and that very limited data are
available to support these opinions. Therefore, we call for
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research to assess the nature and extent of institutional
obstacles to pediatric research and monitoring of pro-
gress in improving the balance in human subject research
regulation by the stakeholder societies.
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Endnotes
Footnote
1OHRP is currently seeking public comment regarding
implementation of such an appeal process [10]. Office
for Human Research Protections (OHRP): Advance
notice of proposed rulemaking (ANPRM), human sub-
jects research protections: Enhancing protections for
research subjects and reducing burden, delay, and ambi-
guity for investigators. 2011:http://www.hhs.gov/ohrp/
humansubjects/anprm2011page.html
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